| Literature DB >> 29044932 |
Thomas M Gorter1, Dirk J van Veldhuisen1, Johann Bauersachs2, Barry A Borlaug3, Jelena Celutkiene4, Andrew J S Coats5,6, Marisa G Crespo-Leiro7, Marco Guazzi8, Veli-Pekka Harjola9, Stephane Heymans10, Loreena Hill11, Mitja Lainscak12, Carolyn S P Lam13, Lars H Lund14, Alexander R Lyon15, Alexandre Mebazaa16, Christian Mueller17, Walter J Paulus18, Burkert Pieske19, Massimo F Piepoli20, Frank Ruschitzka21, Frans H Rutten22, Petar M Seferovic23, Scott D Solomon24, Sanjiv J Shah25, Filippos Triposkiadis26, Rolf Wachter27, Carsten Tschöpe19, Rudolf A de Boer1.
Abstract
There is an unmet need for effective treatment strategies to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in patients with HFpEF was almost exclusively focused on the left side. However, it is now increasingly recognized that right heart dysfunction is common and contributes importantly to poor prognosis in HFpEF. More insights into the development of right heart dysfunction in HFpEF may aid to our knowledge about this complex disease and may eventually lead to better treatments to improve outcomes in these patients. In this position paper from the Heart Failure Association of the European Society of Cardiology, the Committee on Heart Failure with Preserved Ejection Fraction reviews the prevalence, diagnosis, and pathophysiology of right heart dysfunction and failure in patients with HFpEF. Finally, potential treatment strategies, important knowledge gaps and future directions regarding the right side in HFpEF are discussed.Entities:
Keywords: Biomarkers; Heart failure; Heart failure with preserved ejection fraction; Pulmonary hypertension; Right ventricular function
Mesh:
Year: 2017 PMID: 29044932 DOI: 10.1002/ejhf.1029
Source DB: PubMed Journal: Eur J Heart Fail ISSN: 1388-9842 Impact factor: 15.534